- Home
- BCAB vs DXST Comparison
BCAB vs DXST Comparison
Compare BCAB & DXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- DXST
- Stock Information
- Founded
- BCAB 2007
- DXST 2011
- Country
- BCAB United States
- DXST China
- Employees
- BCAB N/A
- DXST N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- DXST
- Sector
- BCAB Health Care
- DXST
- Exchange
- BCAB Nasdaq
- DXST NYSE
- Market Cap
- BCAB 19.9M
- DXST 20.1M
- IPO Year
- BCAB 2020
- DXST 2025
- Fundamental
- Price
- BCAB $0.33
- DXST $1.25
- Analyst Decision
- BCAB Buy
- DXST
- Analyst Count
- BCAB 2
- DXST 0
- Target Price
- BCAB $1.00
- DXST N/A
- AVG Volume (30 Days)
- BCAB 811.8K
- DXST 27.8K
- Earning Date
- BCAB 08-11-2025
- DXST 01-01-0001
- Dividend Yield
- BCAB N/A
- DXST N/A
- EPS Growth
- BCAB N/A
- DXST 13.11
- EPS
- BCAB N/A
- DXST 0.14
- Revenue
- BCAB $11,000,000.00
- DXST $11,542,292.00
- Revenue This Year
- BCAB N/A
- DXST N/A
- Revenue Next Year
- BCAB N/A
- DXST N/A
- P/E Ratio
- BCAB N/A
- DXST $9.09
- Revenue Growth
- BCAB N/A
- DXST 22.18
- 52 Week Low
- BCAB $0.24
- DXST $0.85
- 52 Week High
- BCAB $2.53
- DXST $5.74
- Technical
- Relative Strength Index (RSI)
- BCAB 38.71
- DXST N/A
- Support Level
- BCAB $0.33
- DXST N/A
- Resistance Level
- BCAB $0.37
- DXST N/A
- Average True Range (ATR)
- BCAB 0.04
- DXST 0.00
- MACD
- BCAB -0.00
- DXST 0.00
- Stochastic Oscillator
- BCAB 5.26
- DXST 0.00
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.